Menopause: The Journal of The North American Menopause Society
Vol. 23, No. 9, pp. 1026-1027

Domchek S¹, Kaunitz AM.

Author information

Abstract

As more women are being counseled and tested, clinicians increasingly encounter women with identified BRCA1 and BRCA2 gene mutations. Existing, albeit limited, data indicate that risks of breast cancer are not increased with use of systemic hormone therapy by menopausal BRCA mutation carriers with intact breasts. Young mutation carriers with or without intact breasts should not defer or avoid risk-reducing (and lifesaving) bilateral salpingo-oophorectomy because of concerns that subsequent use of systemic hormone therapy will elevate breast cancer risk.

PMID: 27504919
DOI: 10.1097/GME.0000000000000724

資料來源：PubMed
連結網址：https://www.ncbi.nlm.nih.gov/pubmed/27504919